SCHEMBL6846685

SCHEMBL6846685

O=C(Nc1cccc(CSc2ncnc3[nH]ncc23)c1)c1ccc2ncccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
ACKR3 P25106 1/20 0.45
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SIRT2 Q8IXJ6 2/20 0.44
SIRT1 Q96EB6 2/20 0.44
SIRT3 Q9NTG7 2/20 0.44
POLB P06746 1/20 0.43
PABPC1 P11940 1/20 0.43
BLK P51451 1/20 0.43
BTK Q06187 1/20 0.43
PARP1 P09874 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846526 0.93 NPC1 (0.51) ALDH1A1MAPTMAPK1RAB9ANPC1
SCHEMBL6841324 0.83 SIRT2 (0.55) ALDH1A1MAPTMAPK1SIRT2SIRT1
SCHEMBL6846944 0.83 MAPT (0.48) ALDH1A1MAPTMAPK1SIRT2SIRT1
SCHEMBL6848430 0.82 SIRT2 (0.51) ALDH1A1MAPTMAPK1RAB9ANPC1
SCHEMBL6845380 0.82 ALDH1A1 (0.49) ALDH1A1MAPTMAPK1RAB9ANPC1
SCHEMBL6844684 0.81 ALDH1A1 (0.48) ALDH1A1MAPTMAPK1SIRT2SIRT1
SCHEMBL6845386 0.81 ALDH1A1 (0.66) ALDH1A1MAPTMAPK1RAB9ANPC1
SCHEMBL6846676 0.81 ALDH1A1 (0.46) ALDH1A1MAPTMAPK1SIRT2SIRT1
SCHEMBL6844786 0.81 ALDH1A1 (0.48) ALDH1A1MAPTMAPK1SIRT2SIRT1
SCHEMBL6845344 0.80 ALDH1A1 (0.49) ALDH1A1MAPTMAPK1SIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US claimed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US claimed
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885MAPT 899/4885MAPK1 45/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885MAPT 899/4885MAPK1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.